Pityriasis rosea

Meet the patient

A 22-year-old student noticed a single pink, scaly patch on his chest two weeks ago and treated it as ringworm with no change. This morning he woke to find his trunk covered in dozens of smaller oval pink patches arranged in sweeping lines down his back. He feels well, apart from a mild itch.^[1]

The single skill that settles his consult is the same that settles every PR: recognise the herald-and-Christmas-tree pattern, resist the urge to over-investigate, and decide whether any feature (palms, soles, pregnancy, persistence) forces you off the reassurance pathway. Get that and the rest is detail.^[1]

What PR is — and the two words that anchor it

Pityriasis rosea is an acute, self-limiting inflammatory dermatosis of the papulosquamous group. The clinical signature is a single larger herald patch followed by a generalised eruption of oval, salmon-pink plaques with a peripheral collarette of scale, distributed along the skin cleavage lines in a "Christmas-tree" pattern on the trunk.^[1]

The name carries the diagnosis. Pityriasis means bran-like scale; rosea means pink. Together they describe exactly what you see — pink plaques with a fine flaky collar. A comprehensive classification splits PR into classic and atypical forms, with atypical variants (inverse, vesicular, purpuric, drug-induced) the ones most likely to trap you.^[1]

^[1]

How common, who, and when

PR affects all ages but peaks in adolescents and young adults (10 to 35 years), accounts for roughly 0.5 to 2 percent of dermatology outpatient diagnoses, and is slightly more common in females in some series. Seasonal clustering in spring and autumn in temperate climates supports an infectious trigger.^[2][9]

The epidemiology that earns marks: a mild prodrome (malaise, low-grade fever, headache, lymphadenopathy) in a minority; recurrence is uncommon at about 2 percent; and darker skin phototypes may show more violaceous lesions and more prominent post-inflammatory pigment change. There is no consistent racial or geographical predilection.^[1]

Why it happens — the herpesvirus that woke up

The exact cause is unproven, but the leading hypothesis is endogenous reactivation of human herpesvirus-6 (HHV-6) and/or HHV-7, with a subsequent cell-mediated immune response in the skin. Viral DNA has been detected in plasma, peripheral blood mononuclear cells, saliva, and lesional skin by PCR; calibrated quantitative real-time PCR on paired plasma and skin raises detection and supports active replication rather than incidental latency.^[2][3]

Both HHV-6 (variants A and B) and HHV-7 are beta-herpesviruses that establish lifelong latency after primary infection in early childhood — HHV-6 typically by age two (roseola infantum), HHV-7 slightly later. Latency lives in CD34+ progenitors, T lymphocytes, monocytes, and salivary gland epithelium. Roughly 0.5 to 1 percent of people carry chromosomally integrated HHV-6 (ciHHV-6), which complicates PCR interpretation because a positive whole-blood result reflects integrated DNA, not active replication.^[1]

^{[2] [3] [7]}

The mechanism-to-feature map: a trigger permits reactivation → viraemia → cutaneous seeding (the herald patch is the first focus) → a Th1 CD4+ T-cell response generates the secondary eruption → the virus returns to latency and the rash resolves. PR lesions show a CD4+ T-cell infiltrate and Langerhans cells, consistent with a host immune response to viral antigen.^[2]

The clinical story — herald patch, then the forest

The herald patch comes first. It appears in 50 to 90 percent of cases, one to two weeks before the generalised eruption — a single oval, salmon-pink plaque, 2 to 5 cm across, with a collarette of scale, on the trunk, neck, or proximal limb. It is the lesion most often misdiagnosed as tinea corporis.^[1]

The secondary eruption follows in crops over 7 to 14 days — multiple smaller oval papules and plaques, typically 0.5 to 2 cm, over the trunk and proximal extremities, sparing the face and distal limbs in classic cases. The long axes of the oval lesions align along the skin cleavage lines (Langer lines), producing the "Christmas-tree" pattern on the back. Lesions may be mildly pruritic; intense itching is uncommon and should prompt a search for an alternative diagnosis.^[1][4][9]

The classic trap: the herald patch treated as ringworm with topical antifungal — and the secondary eruption then labelled "drug allergy" or "guttate psoriasis." The collarette scale and the Christmas-tree distribution on the trunk, sparing palms and soles, make the call.^[1]

The atypical 20 percent — the cases that bite

Up to 20 percent of pityriasis rosea cases deviate from classic morphology, and these are the ones most likely to present to a tertiary clinic, an emergency department, or an obstetrics clinic. Recognising the atypical subtype is the single highest-yield fellowship skill in this topic.^[1]

^{[1] [1] [1] [13]}

The differential — secondary syphilis is the one you must not miss

The differential of a generalised papulosquamous eruption is wide, but one mimic is non-negotiable: secondary syphilis. Get the face-off right and the rest follows.^[1]

^{[1] [13] [14] [15] [16]}

The discriminator line: palms and soles involved, plus lymphadenopathy, plus a positive RPR = secondary syphilis, not PR. Palmar and plantar lesions are an exclusion criterion for PR in the validated Chuh criteria — their presence forces you to test.^[4]

The Chuh criteria — the validated bedside rule

The Chuh diagnostic criteria (2003) allow a clinical diagnosis without laboratory testing in classic cases. They are reproduced verbatim because examiners reward precision:^[4]

Essential features (all required): discrete circular or oval lesions; scaling on most lesions; peripheral collarette scaling with central clearance on at least two lesions.^[4]

Optional features (at least one required): truncal and proximal limb distribution (fewer than 10 percent of lesions distal to mid-upper-arm and mid-thigh); orientation of most lesions along skin cleavage lines (Christmas-tree); a herald patch at least two days before the secondary eruption.^[4]

Exclusion criteria (none may be present): multiple small vesicles at the centre of two or more lesions; two or more lesions on palmar or plantar skin. Their presence rules PR out and broadens the work-up.^[4]

Dermoscopy — the confirmatory glance

Dermoscopy is useful when the diagnosis is uncertain or the herald patch is atypical. The characteristic pattern is a peripheral collarette of scale pointing inwards, with patchy peripheral dotted vessels in 35 to 65 percent and a central yellowish background on a peripheral reddish base in roughly 40 percent. In darker phototypes the background may appear more violaceous with white scales.^[1]

^{[10] [11]}

Investigations — almost none, except to exclude mimics

Pityriasis rosea is primarily a clinical diagnosis. Investigation is reserved for atypical cases or when the differential includes conditions requiring laboratory confirmation.^[1]

• RPR/VDRL plus treponemal test — exclude secondary syphilis in atypical or high-risk patients, or whenever palms or soles are involved.
• KOH preparation or fungal culture — exclude tinea corporis when the herald patch is atypical.
• Skin biopsy — atypical cases; the histology is nonspecific but helps exclude psoriasis, lichen planus, and mycosis fungoides.
• HHV-6/7 PCR — research or selected refractory cases; not routine.^[4][13]

PR histology is nonspecific and resembles subacute spongiotic dermatitis: focal parakeratosis with mounds of scale, spongiosis with small spongiotic vesicles, a diminished or absent granular layer, erythrocyte extravasation, and a superficial perivascular lymphohistiocytic infiltrate. Eosinophils may be present, particularly in drug-induced cases. These findings exclude psoriasis, lichen planus and mycosis fungoides but cannot alone confirm PR.^[8]

Management — reassurance is the treatment

The cornerstone of management is reassurance: PR is self-limiting and benign in the vast majority of patients. Explain that most lesions resolve within 6 to 8 weeks (sometimes up to 12), recommend emollients and mild cleansers, and advise against hot baths, vigorous rubbing, and irritating topicals.^[1][5][13]

For itch: non-sedating antihistamines (sedating at night if sleep is disturbed), mild-to-moderate potency topical corticosteroids for 1 to 2 weeks, and calamine or menthol preparations for symptomatic relief.^[5][6]

Active pharmacological therapy is reserved for extensive, persistent, or highly symptomatic disease. The Cochrane review (2019) found oral acyclovir may improve rash clearance (evidence for itch is inconclusive) and erythromycin may reduce pruritus.^[6]

^{[1] [5] [6]}

The treatment ladder: mild/classic PR — reassurance plus emollients plus or minus an antihistamine; moderate pruritus — add a mild-to-moderate topical corticosteroid; extensive, early, or highly symptomatic — consider oral acyclovir or valaciclovir; persistent or refractory — narrowband UVB phototherapy, and biopsy if atypical.^[1][12]

The classic trap — over-treating a self-limiting disease. Systemic corticosteroids do not alter the natural history of PR and may cause rebound. Do not prescribe them for uncomplicated disease.^[1]

The pregnancy red flag — the one thing that is not benign

Pityriasis rosea in pregnancy is the most important red flag in this topic. The landmark Drago series (JAAD 2008) reported an overall preterm delivery rate of about 24 percent and a spontaneous abortion rate of about 13 percent — and among women with onset before 15 weeks gestation, the spontaneous abortion rate was markedly higher.^[7]

^[7]

Subsequent studies report lower rates, but early gestational onset, widespread rash, constitutional symptoms, and high HHV-6 viral load remain the risk factors. Management means obstetric co-management and targeted fetal surveillance — reassurance alone is insufficient.^[5][7]

How patients come to harm — the preventable list

PR is benign and self-limiting in almost everyone, so the preventable harms are errors of omission and commission:^[1]

• Missing secondary syphilis by labelling an atypical eruption "just PR" — the mimic with palms-and-soles involvement that demands an RPR.
• Missing the pregnancy red flag and reassuring an early-pregnancy patient without obstetric referral.
• Over-treating with systemic steroids that do not help and may rebound.
• Ignoring persistence beyond 3 months — the case that is in fact mycosis fungoides or a drug eruption.
• Misdiagnosing the herald patch as tinea and treating with antifungal for weeks.^[1]

Prognosis, disposition, and special populations

PR is self-limiting: most cases resolve within 6 to 12 weeks without scarring, though post-inflammatory hyper- or hypopigmentation may persist for weeks to months in darker skin types, and recurrence is uncommon.^[5][13]

Follow-up is required when pregnancy is diagnosed or suspected, the rash persists beyond 3 months, atypical morphology or systemic symptoms develop, or treatment response is inadequate. Children have more atypical presentations (face and scalp may be involved) and management is supportive; pregnancy demands obstetric co-management, emollients and mild topical steroids, and a documented gestational age at onset.^[1][7]

Evidence and regional deltas

The European Academy of Dermatology and Venereology position statement (Chuh et al., 2016) emphasises reassurance, symptomatic care, and judicious acyclovir, erythromycin or phototherapy for selected patients. The Cochrane review (2019) concluded acyclovir may improve clearance (itch evidence inconclusive) and erythromycin may reduce pruritus.^[5][6]

Regional deltas: in tropical and darker-skinned populations, lesions may appear more violaceous and post-inflammatory pigment change more prominent; where syphilis prevalence is high, a lower threshold for RPR/VDRL testing is appropriate.^[1]

The mantra, and the mnemonic

The mantra: herald patch, Christmas tree, collarette scale — reassure, and reach for the RPR only when the palms are involved.^[1]

Ward-round test — three stems, thirty seconds each

Stem 1 — the herald patch treated as ringworm (answer)ShowHide

A 22-year-old man has a single oval scaly patch on his chest for two weeks that did not respond to antifungal cream. Today his trunk broke out in dozens of smaller oval pink plaques sweeping down his back in lines. What is the diagnosis, and what bedside sign confirms it? Model: This is classic pityriasis rosea — a herald patch followed one to two weeks later by a secondary eruption of oval plaques with a peripheral collarette of scale arranged along skin cleavage lines in a Christmas-tree distribution. The confirmatory bedside sign is the collarette scale pointing inwards; KOH is negative (excluding tinea), palms and soles are spared (excluding secondary syphilis). Reassure: self-limiting over 6 to 12 weeks; emollients and an antihistamine for itch.^[1]

Stem 2 — the atypical eruption with palmar lesions (answer)ShowHide

A 28-year-old with a widespread papulosquamous eruption now has copper-red lesions on his palms and soles and palpable cervical lymphadenopathy. The registrar calls it pityriasis rosea. What is wrong with that diagnosis, and what is the single most important test? Model: Palmar and plantar lesions are an exclusion criterion for pityriasis rosea in the validated Chuh criteria — their presence rules PR out. Copper-red lesions on palms and soles plus generalised lymphadenopathy point to secondary syphilis. The single most important test is an RPR/VDRL plus a treponemal test; a reactive result confirms the diagnosis. Treatment is intramuscular benzathine penicillin G 2.4 million units, plus partner notification and an STI screen.^[4]

Stem 3 — pityriasis rosea at 10 weeks gestation (answer)ShowHide

A 26-year-old woman at 10 weeks gestation develops a herald patch and a widespread pityriasis rosea eruption with malaise. She is reassured it is benign and sent home. What was missed? Model: Early-pregnancy onset is the single most important red flag in pityriasis rosea. In the landmark Drago series, women with onset before 15 weeks gestation had a spontaneous abortion rate of roughly 62 percent, against about 4 percent with later-onset disease. Reassurance alone is insufficient — she needs immediate obstetric co-management and targeted fetal surveillance, documentation of gestational age at onset, and counselling about the early-pregnancy risk. Emollients and mild topical corticosteroids are safe; weigh acyclovir on risk-benefit.^[7]

References16ShowHide

1. [1]Drago F, Broccolo F, Rebora A, et al. Pityriasis Rosea: A Comprehensive Classification Dermatology, 2016.PMID 27096928
2. [2]Drago F, Broccolo F, Rebora A. Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology J Am Acad Dermatol, 2009.PMID 19615540
3. [3]Aydin Kurc M, Erfan G, Kaya AD, et al. Association between Pityriasis Rosea (PR) and HHV-6/HHV-7 Infection: Importance of Sample Selection and Diagnostic Techniques Diagnostics (Basel), 2024.PMID 38667488
4. [4]Chuh AA. Diagnostic criteria for pityriasis rosea: a prospective case control study for assessment of validity J Eur Acad Dermatol Venereol, 2003.PMID 12602987
5. [5]Chuh A, Zawar V, Sciallis G, et al. A position statement on the management of patients with pityriasis rosea J Eur Acad Dermatol Venereol, 2016.PMID 27406919
6. [6]Contreras-Ruiz J, Peternel S, Jiménez Gutiérrez C, et al. Interventions for pityriasis rosea Cochrane Database Syst Rev, 2019.PMID 31684696
7. [7]Drago F, Broccolo F, Zaccaria E, et al. Pregnancy outcome in patients with pityriasis rosea J Am Acad Dermatol, 2008.PMID 18489054
8. [8]Prasad D, Mittal RR, Walia R, et al. Pityriasis rosea: A histopathologic study Indian J Dermatol Venereol Leprol, 2000.PMID 20877089
9. [9]Shende AA, Chikhalkar SB A Cross-Sectional Study of Epidemiological and Clinical Aspects of Pityriasis Rosea along with Dermoscopic Analysis and Histopathology Correlation Indian J Dermatol, 2024.PMID 38841213
10. [10]Vasisht S, Kansal NK. Dermoscopic features of pityriasis rosea BMJ Case Rep, 2023.PMID 37816577
11. [11]Nwako-Mohamadi MK, Masenga JE, Mavura D, et al. Dermoscopic Features of Psoriasis, Lichen Planus, and Pityriasis Rosea in Patients With Skin Type IV and Darker Attending the Regional Dermatology Training Centre in Northern Tanzania Dermatol Pract Concept, 2019.PMID 30775148
12. [12]Jairath V, Mohan M, Jindal N, et al. Narrowband UVB phototherapy in pityriasis rosea Indian Dermatol Online J, 2015.PMID 26500862
13. [13]Litchman G, Le JK. Pityriasis Rosea 2026.PMID 28846360
14. [14]Sudibyo W, Qurrohman T. Secondary Syphilis in a 21-Year-Old Woman With Diffuse Mucocutaneous Lesions: A Case Report and Diagnostic Review Cureus, 2025.PMID 40951227
15. [15]Leung AK, Barankin B, Lam JM, Leong KF. Childhood guttate psoriasis: an updated review Drugs Context, 2023.PMID 37908643
16. [16]Rajagopalan M, Inamadar A, Mittal A, et al. Expert Consensus on The Management of Dermatophytosis in India (ECTODERM India) BMC Dermatol, 2018.PMID 30041646